rs1042522 — TP53 Pro72Arg

p53 codon 72 polymorphism producing two functionally distinct proteins — Arg72 with stronger apoptotic activity, Pro72 favoring cell cycle arrest and DNA repair — with population data associating Pro/Pro with ~3 years longer median lifespan

See your personal result for TP53

Upload your DNA data to find out which genotype you carry and what it means for you.

Upload your DNA data

Works with 23andMe, AncestryDNA, and other DNA test exports. Results in under 60 seconds.

TP53 Pro72Arg — The Guardian of the Genome's Longevity Switch

p53 is one of the most studied proteins in all of biology, nicknamed the "guardian of the genome" for its central role in deciding a cell's fate after DNA damage. When a cell's DNA is damaged — by UV radiation, chemical carcinogens, replication errors, or oxidative stress — p53 is activated and must make a critical decision: arrest the cell cycle to allow repair, or trigger apoptosis 11 Programmed cell death — the cell self-destructs to prevent potentially cancerous replication of damaged DNA and destroy it entirely.

The Pro72Arg polymorphism at codon 72 of TP53 produces two versions of the p53 protein with measurably different functional priorities. The Arg72 form is optimized for apoptosis; the Pro72 form favors cell cycle arrest and DNA repair. This is not a simple "good vs. bad" distinction — it reflects a fundamental biological tradeoff that has real consequences for cancer susceptibility, cellular aging, and longevity.

The Mechanism

The polymorphism lies in the proline-rich domain of p53, a region required for full apoptotic signaling. Dumont et al., 200322 Dumont et al., 2003
Dumont P et al. The codon 72 polymorphic variants of p53 have markedly different apoptotic potential. Nature Genetics, 2003 demonstrated that Arg72 p53 induces apoptosis far more efficiently than Pro72 p53. The mechanism: Arg72 p53 preferentially localizes to the mitochondria, where it triggers cytochrome c release into the cytosol, activating the intrinsic apoptotic cascade. Pro72 p53 is more nuclear and preferentially activates transcription of DNA damage-repair genes and G1 cell cycle arrest genes.

The two alleles thus represent a molecular dial between two complementary tumor-suppression strategies: Arg72 eliminates damaged cells (apoptosis), while Pro72 attempts to fix them (repair and checkpoint). Under high genotoxic load — for example, chronic carcinogen exposure — the apoptotic strategy of Arg72 might seem preferable. But in normal aging, where most DNA damage is manageable and cellular senescence 33 Cellular senescence is a state where cells permanently stop dividing but remain metabolically active. Excessive senescent cell accumulation contributes to tissue dysfunction and age-related disease accumulates from excess apoptosis, the more conservative Pro72 strategy may preserve tissue integrity better over a lifetime.

The Evidence

The landmark longevity study by Ørsted et al.44 Ørsted et al.
Ørsted DD, Bojesen SE et al. Tumor suppressor p53 Arg72Pro polymorphism and longevity, cancer survival, and risk of cancer in the general population. Journal of Experimental Medicine, 2007 followed 9,219 Danish individuals (ages 20–95) with complete 12-year registry follow-up. Their key finding: Pro/Pro homozygotes showed a 6% increase in 12-year survival compared to Arg/Arg homozygotes, corresponding to approximately 3 years of increased median lifespan. Heterozygotes showed an intermediate 3% survival increase. The longevity effect was not explained by lower cancer incidence — in fact, the Arg72Pro variant did not significantly reduce cancer risk overall — but by better survival after cancer diagnosis (HR 0.74 for 5-year cancer mortality in Pro/Pro vs. Arg/Arg, meaning a 26% reduction in post-cancer mortality).

A large replication effort by Kodal et al.55 Kodal et al.
Kodal JB et al. TP53 Arg72Pro, mortality after cancer, and all-cause mortality in 105,200 individuals. Scientific Reports, 2017 in 105,200 contemporary Danes did not reproduce the all-cause mortality effect (HR 1.09, 95% CI 0.98–1.21 for Pro/Pro vs. Arg/Arg; not significant). The authors suggest secular trends — changes in cancer treatment, carcinogen exposures, and lifestyle over time — may explain why the older cohort (1987–1999) showed the effect while the modern cohort did not. This does not necessarily negate the biological mechanism, but it indicates the longevity effect is not immutable and depends on environmental context.

A separate line of evidence comes from mitochondrial DNA integrity. A study of 425 aged subjects66 425 aged subjects
Altilia S et al. TP53 codon 72 polymorphism affects accumulation of mtDNA damage in human cells. Aging, 2012 found that Arg72 p53 co-localizes more strongly with DNA polymerase gamma (the mitochondrial DNA repair enzyme) than Pro72 p53, and individuals homozygous for Arg72 showed lower accumulation of mitochondrial DNA heteroplasmy with aging. This suggests Arg72 may actually protect mitochondrial DNA, even while driving more nuclear DNA apoptosis.

Practical Implications

The Pro72Arg variant illustrates why "cancer prevention" and "longevity" are not synonymous goals. The Arg72 form destroys more damaged cells more aggressively — but this also means more cells are eliminated over a lifetime. If the apoptosed cells are truly pre-cancerous, this is protective. If they are merely cells with minor, repairable damage, it accelerates tissue depletion and may contribute to the hallmarks of aging.

For Arg/Arg carriers (CC genotype), the key implication is that DNA damage avoidance becomes especially important, since the cellular response is to destroy rather than repair. Minimizing mutagen exposure — particularly UV radiation, tobacco carcinogens, and occupational genotoxins — reduces the frequency with which the apoptotic pathway is triggered. Supporting DNA repair mechanisms through antioxidants that reduce the initial DNA damage burden is also rational. Regular cancer screening reflects the elevated post-damage stakes of an apoptosis-dominant genome guardian.

For Pro/Pro carriers (GG genotype), cell cycle arrest and DNA repair are prioritized. This appears to translate to better survival after a cancer diagnosis and potentially longer life. The tradeoff is a slightly longer window between damage and elimination of damaged cells, which could in theory allow more time for additional mutations to accumulate in arrested cells.

Interactions

The most documented interaction is with MDM2 (rs2279744, MDM2 promoter SNP 309 T>G). MDM2 is the primary negative regulator of p53 — it binds p53 and targets it for degradation. The MDM2 rs2279744 G allele increases MDM2 expression 2-4 fold, dampening all p53 activity. Combining TP53 rs1042522 with MDM2 rs2279744 affects the net level of p53 tumor suppression: carriers of both the Arg72 TP53 and high-MDM2 MDM2 genotypes experience blunted p53 apoptotic function from two independent directions. Multiple studies have examined this compound genotype in cancer risk. The combined Arg/Arg + MDM2 G/G genotype represents a candidate compound action, as the recommendation — aggressive DNA damage avoidance and cancer surveillance — differs from either single-variant recommendation alone and is supported by mechanistic data from multiple groups.

The MC1R rs1805007 variant (red hair, reduced melanin photoprotection) is also relevant: Arg72 carriers have more to lose from UV-induced DNA damage, and impaired melanin photoprotection (MC1R T allele) compounds that vulnerability. This combination has been studied in melanoma risk in European populations.

Genotype Interpretations

What each possible genotype means for this variant.

GG Pro/Pro Beneficial

Both copies encode the repair-favoring Pro72 form of p53

The Pro72 form of p53 preferentially activates transcription of DNA repair genes and cell cycle checkpoint genes rather than triggering immediate apoptosis. This means that when your cells sustain DNA damage, they are more likely to halt division, attempt repair, and re-enter the cell cycle successfully — rather than undergo programmed death.

The longevity association for Pro/Pro in the original study was driven not by prevention of cancer but by better survival after cancer diagnosis (HR 0.74 for 5-year post-cancer mortality vs. Arg/Arg). This suggests that the repair-oriented p53 response may matter most once cancer has developed: damaged tumor suppressor pathways may respond better to chemotherapy when residual p53 function is preserved through cell cycle arrest.

The larger 2017 replication in 105,200 individuals did not confirm a significant all-cause mortality benefit in a modern cohort. The biological mechanism is established; the magnitude of the longevity effect in contemporary environments (with modern cancer treatments and reduced carcinogen exposure) remains uncertain.

CG Arg/Pro Intermediate

One Arg72 and one Pro72 copy — intermediate apoptosis-repair balance

The heterozygous state is functionally codominant: cells express both the Arg72 and Pro72 forms of p53 simultaneously. Studies have generally found intermediate effects for heterozygotes, consistent with both proteins being active in the same cell. The net p53 response involves both enhanced apoptotic signaling (from Arg72) and enhanced cell cycle arrest and repair gene transcription (from Pro72).

From a practical standpoint, the Arg/Pro genotype carries a moderate reduction in one of the potential longevity mechanisms identified in the original Danish cohort, though the effect size for heterozygotes is modest and the finding was not replicated in the larger contemporary study.

CC Arg/Arg High Risk

Both copies encode the pro-apoptotic Arg72 form of p53

The Arg72 form of p53 preferentially localizes to mitochondria upon DNA damage activation, where it triggers cytochrome c release and apoptotic cell death. This is a highly effective tumor-suppression strategy: damaged cells are eliminated before they can accumulate additional mutations. However, over a lifetime, this approach may deplete tissue cell populations more aggressively, potentially contributing to accelerated aging in stem cell compartments.

The evidence for a longevity disadvantage is genuine but contested. The original Ørsted et al. study found a 6% lower 12-year survival rate compared to Pro/Pro. The larger Bojesen et al. replication in a modern cohort found no significant difference. The biological mechanism is real; whether it translates to clinically meaningful lifespan differences in the modern environment (better cancer treatment, less carcinogen exposure) remains uncertain.

For cancer risk specifically, the picture is complex. The Arg72 form is more susceptible to degradation by the HPV E6 oncoprotein, which may explain population-level associations with cervical cancer risk in HPV-positive women.